Global ETD Search

1	Evidence-based guidelines for pharmacological treatment of anxiety disorders Baldwin, David S., Anderson, Ian M., Nutt, David J., Bandelow, Borwin, Bond, Alyson, Davidson, Jonathan R. T., den Boer, Johan A., Fineberg, Naomi A., Knapp, Martin, Scott, Jan, Wittchen, Hans-Ulrich 30 January 2013 (has links) (PDF) These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments. Antiepileptika Antidepressiva Antipsychotika Angststörungen Anxiolytika Benzodiazepane kognitive Verhaltenstherapie evidenzbasierte Richtlinien generalisierte Angststörung Zwangsstörung Panikstörung posttraumatische Belastungsstörung Phobie Behandlung SSRI Venlafaxin Anticonvulsants antidepressants antipsychotics anxiety disorders anxiolytics benzodiazepines cognitive behaviour therapy evidence-based guidelines generalised anxiety disorder obsessive-compulsive disorder panic disorder post-traumatic stress disorder simple phobia social phobia SSRI treatment venlafaxine ddc:150 rvk:CU 3100 rvk:CU 8500
2	Evidence-based guidelines for pharmacological treatment of anxiety disorders: Recommendations from the British Association for Psychopharmacology Baldwin, David S., Anderson, Ian M., Nutt, David J., Bandelow, Borwin, Bond, Alyson, Davidson, Jonathan R. T., den Boer, Johan A., Fineberg, Naomi A., Knapp, Martin, Scott, Jan, Wittchen, Hans-Ulrich January 2005 (has links) These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in anxiety disorders reviewed the main subject areas and considered the strength of evidence and its clinical implications. The guidelines were constructed after extensive feedback from participants and interested parties. The strength of supporting evidence for recommendations was rated. The guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments. info:eu-repo/classification/ddc/150 ddc:150
3	Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology Baldwin, David S., Anderson, Ian M., Nutt, David J., Allgulander, Christer, Bandelow, Borwin, den Boer, Johan A., Christmas, David M., Davies, Simon, Fineberg, Naomi, Lidbetter, Nicky, Malizia, Andrea, McCrone, Paul, Nabarro, Daniel, O’Neill, Catherine, Scott, Jan, van der Wee, Nic, Wittchen, Hans-Ulrich 17 September 2019 (has links) This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees. info:eu-repo/classification/ddc/610 ddc:610

1

Page generated in 0.0195 seconds